For the first time ever, some of India's biggest pharmaceutical companies, cutting across their respective associations and representing nearly half the Rs 93,000 crore market, have come together to push for ethical marketing practices to clean up the industry's image.
The forum, comprising of 40 to 50 domestic and MNC firms, had its first closed-door meeting on October 14. It has made a "voluntary and moral commitment" to follow ethical marketing practices in "letter and spirit", and will work with the regulatory mechanism to facilitate the exercise.
Uttar Pradesh Government Contemplates Special Initiatives for Pharma Sector
We are seriously considering facilitative provisions for pharma and drugs industry, said the principal secretary of the state industrial development department.
Advertisement
Earlier attempts at bringing about a code acceptable to the entire industry had failed, as the associations the Indian Pharmaceutical Alliance (representing domestic firms), MNCs-led Organisation of Pharmaceutical Producers of India (OPPI) and the Indian Drug Manufacturers' Association (IDMA) were at loggerheads.
This comes even as the government has already expressed its intention to make the 'Uniform Code of Pharmaceutical Marketing Practices' mandatory from next year. The code banning cruise tickets, freebies and paid vacations for doctors sponsored by drug companies is voluntary at present. But in light of rampant violations, the government plans to make it binding on companies.
![Indian Pharmaceutical Companies Told to Develop Drugs for Lifestyle Diseases Like Diabetes]( "Indian Pharmaceutical Companies Told to Develop Drugs for Lifestyle Diseases Like Diabetes")
Maharashtra Governor C.V. Rao has asked the Indian pharmaceutical companies to develop drugs for lifestyle diseases like diabetes, hypertension and heart ailments.
The group which includes top MNCs like Novartis, MSD and Abbott, and domestic firms Sun Pharma, Zydus Cadila and Dr Reddy's among others wants to start a movement and build pressure on those who are not following ethical practices. A "voluntary" coming together out of sheer "moral commitment carries greater weightage" than guidelines being thrust on them, said an expert, who is part of the forum. "We have come together voluntarily to push for ethical marketing practices," IPA director general D G Shah said. "Over the years, our industry has been maligned."
The 'Forum of Pharmaceutical Ethical Marketing Practices' will draw a core working group from the firms to decide the modalities of taking the "movement" forward, and is in favour of a body similar to the Advertising Council of India which is not a statutory body, to regulate the code. A final proposal will be drawn up soon. Even after the code kicked in this year, complaints continued, with many saying it existed only on paper, as firms try to influence prescriptions. "We plan to seek clarifications from the government so that it (the code) is tweaked into a more practical and implementable code," said Ranjana Smetacek, director general, OPPI.
Source: Medindia
Indian Pharmaceutical Companies Told to Develop Drugs for Lifestyle Diseases Like Diabetes
Maharashtra Governor C.V. Rao has asked the Indian pharmaceutical companies to develop drugs for lifestyle diseases like diabetes, hypertension and heart ailments.
Advertisement
The group which includes top MNCs like Novartis, MSD and Abbott, and domestic firms Sun Pharma, Zydus Cadila and Dr Reddy's among others wants to start a movement and build pressure on those who are not following ethical practices. A "voluntary" coming together out of sheer "moral commitment carries greater weightage" than guidelines being thrust on them, said an expert, who is part of the forum. "We have come together voluntarily to push for ethical marketing practices," IPA director general D G Shah said. "Over the years, our industry has been maligned."
The 'Forum of Pharmaceutical Ethical Marketing Practices' will draw a core working group from the firms to decide the modalities of taking the "movement" forward, and is in favour of a body similar to the Advertising Council of India which is not a statutory body, to regulate the code. A final proposal will be drawn up soon. Even after the code kicked in this year, complaints continued, with many saying it existed only on paper, as firms try to influence prescriptions. "We plan to seek clarifications from the government so that it (the code) is tweaked into a more practical and implementable code," said Ranjana Smetacek, director general, OPPI.
Source: Medindia
Competition Commission of India Extends Deadline for Bids to Conduct Pharma Study
Entities interested in conducting baseline study in the pharma sector and healthcare delivery system in NCR region can now submit their bids till November 5.
Advertisement
U.S. FDA Temporarily Stops Zafgen Biopharmaceutical’s Obesity Drug Trials
The company said the decision of the U.S. drug regulator would affect all ongoing and planned trials involving its lead drug, called beloranib.
Advertisement
Recommended Reading
Latest Drug News
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.
In myeloma (blood cancer) cells, cancer-promoting potential of the fatty acid binding proteins was found to determine to be a valid target for myeloma therapeutics
Acute liver failure cases dropped after the Food and Drug Administration rule to lower the dosage of acetaminophen
